Hereditary Breast and Ovarian Cancer, from the View Point of Gynecology

Abstract

It is difficult to assess whether the ovarian tumor is benign or malignant before operation and frequently to achieve cure even in early detection of the cancer. The risk-reducing salpingo-oophorectomy, therefore, is currently regarded as preventive intervention with the highest certainty for the patients with ovarian cancer that appears with hereditary breast and ovarian cancer (HOBC). As ovarian cancer requires different surveillance from breast cancer, close coordination of gynecologists and breast medicals are required. PARP-inhibitor Olaparib is known to be new molecular target medication towards the patients with ovarian cancers harboring BRCA1/2 genetic alteration. Clinical trials with Olaparib are currently on going.